摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-3-氯(1h)吲唑 | 54768-48-8

中文名称
4-氨基-3-氯(1h)吲唑
中文别名
3-氯-1H-吲唑-4-胺
英文名称
3-Chloro-1H-indazol-4-amine
英文别名
3-chloro-2H-indazol-4-amine
4-氨基-3-氯(1h)吲唑化学式
CAS
54768-48-8
化学式
C7H6ClN3
mdl
MFCD09263202
分子量
167.598
InChiKey
HNLMMCOMDHTWKG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    408.7±25.0 °C(Predicted)
  • 密度:
    1.533±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    54.7
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Inhibitors of the tyrosine kinase EphB4. Part 3: Identification of non-benzodioxole-based kinase inhibitors
    摘要:
    Starting from the initial bis-anilinopyrimidine 1, good potency against EphB4 was retained when benzodioxole at C-4 was replaced by an indazole. The key interactions of the indazole with the protein were characterised by crystallographic studies. Further optimisation led to compound 20, a potent inhibitor of the EphB4 and Src kinases with good pharmacokinetics in various preclinical species and high fraction unbound in plasma. Compound 20 may be used as a tool for evaluating the potential of EphB4 kinase inhibitors in vivo.
    DOI:
    10.1016/j.bmcl.2010.08.100
  • 作为产物:
    描述:
    3-氯-4-硝基(1H)吲唑 在 ammonium chloride 作用下, 以89 %的产率得到4-氨基-3-氯(1h)吲唑
    参考文献:
    名称:
    TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME
    摘要:
    Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    公开号:
    US20230142913A1
点击查看最新优质反应信息

文献信息

  • PYRIMIDINE DERIVATIVES
    申请人:Kettle Jason Grant
    公开号:US20110046108A1
    公开(公告)日:2011-02-24
    The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R 1 , ring A, n, R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.
    这项发明涉及Formula (I)的苯甲酰胺化合物或其药用可接受的盐,其中R1、环A、n、R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法、含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途,用于预防或治疗对EphB4、EphA2和/或Src激酶抑制敏感的肿瘤或其他增殖病症。
  • Synthesis, antiproliferative and apoptotic activities of N-(6(4)-indazolyl)-benzenesulfonamide derivatives as potential anticancer agents
    作者:Najat Abbassi、Hakima Chicha、El Mostapha Rakib、Abdellah Hannioui、Mdaghri Alaoui、Abdelouahed Hajjaji、Detlef Geffken、Cinzia Aiello、Rosaria Gangemi、Camillo Rosano、Maurizio Viale
    DOI:10.1016/j.ejmech.2012.09.013
    日期:2012.11
    possess many types of biological activities, including anticancer activity. The present work reports the synthesis and antiproliferative evaluation of some N-(6(4)-indazolyl)benzenesulfonamides and 7-ethoxy-N-(6(4)-indazolyl)benzenesulfonamides. All compounds were evaluated for their in vitro antiproliferative activity against three tumor cell lines: A2780 (human ovarian carcinoma) A549 (human lung
    最近,已经报道带有磺酰胺部分的化合物具有许多类型的生物学活性,包括抗癌活性。本工作报告了一些N-(6(4)-吲唑基)苯磺酰胺和7-乙氧基-N-(6(4)-吲唑基)苯磺酰胺的合成和抗增殖评价。 评估了所有化合物对三种肿瘤细胞系的体外抗增殖活性:A2780(人类卵巢癌),A549(人类肺腺癌)和P388(鼠白血病)。结果表明,磺酰胺2C,3C,6D,8,13,3B和16被赋予与化合物的药理学上感兴趣的抗增殖活性2C和3C示出了下IC 50(分别从0.50±0.09至1.83±0.52μM和从0.58±0.17至5.83±1.83μM)。此外,这些吲唑能够通过上调典型的凋亡标记p53和bax来触发凋亡。 由于考虑到这些化合物的假设的目标,一个初步对接分析表明,所有的化合物似乎与β微管蛋白相互作用,特别是化合物3b中的是显示出低ķ我。细胞周期阶段的细胞荧光分析表明,所有化合物以其IC 75给药时,都会导致细胞周期的G2
  • Compositions de teinture des fibres kératiniques contenat des dérivés d'indazoles amines et procédé de teinture
    申请人:L'OREAL
    公开号:EP0904769B1
    公开(公告)日:2002-09-25
  • US4036976A
    申请人:——
    公开号:US4036976A
    公开(公告)日:1977-07-19
  • US6027538A
    申请人:——
    公开号:US6027538A
    公开(公告)日:2000-02-22
查看更多